Off-target effects of c-MET inhibitors on thyroid cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Aberrant c-MET signaling is implicated in various cancers, driving the development of targeted inhibitors.
• Thyroid cancer, particularly anaplastic thyroid cancer, often exhibits high c-MET expression.

Purpose of the Study:

• To investigate the efficacy of c-MET inhibitors (tivantinib and crizotinib) in thyroid cancer cell lines.
• To elucidate the mechanisms underlying the antitumor activity of these inhibitors.

Main Methods:

• Screening of eight thyroid cancer cell lines for c-MET expression.
• Treatment with tivantinib and crizotinib to assess growth inhibition, apoptosis, and cell-cycle arrest.
• siRNA-mediated knockdown of c-MET to evaluate its role in drug response.
• In vivo studies using immunodeficient mice xenograft models.

Main Results:

• All tested thyroid cancer cell lines expressed c-MET protein.
• Tivantinib and crizotinib inhibited the growth of 50% of the cell lines, inducing apoptosis and G(2)-M cell-cycle arrest.
• Crizotinib's growth inhibition exceeded its direct c-MET phosphorylation inhibition in specific cell lines (SW1736, TL3).
• siRNA targeting c-MET did not replicate the observed cell-cycle arrest or apoptosis.
• In vivo, crizotinib significantly suppressed thyroid cancer xenograft growth.

Conclusions:

• Tivantinib and crizotinib demonstrate antitumor activity against aggressive thyroid cancer.
• The therapeutic benefits of these c-MET inhibitors are attributed to significant off-target effects.
• Further research into the non-MET-targeting mechanisms is warranted for optimizing thyroid cancer therapy.